Hsin-Yun Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hsin-Yun Wu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Shu-Chen Wei
Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
7 shared publications - Meng-Tzu Weng
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
6 shared publications - Chi-Nien Chen
Department of Pediatrics, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan
2 shared publications Chien-Chih Tung
Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
2 shared publications- Chien-Chih Tung
Department of Integrated Diagnostics and Therapeutics and Medical Research, National Taiwan University Hospital, Taipei, Taiwan
2 shared publications Chiuan-Bo Huang
Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsin-Chu, Taiwan
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
- 19 May 2026
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
Open AccessReal-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
Real-world use and perceptions of advanced combined therapies in treating inflammatory bowel disease
- Open Access
- 22 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 561-565
Demodicosis Mimics Acneiform Eruptions in Patients With Inflammatory Bowel Disease Receiving Upadacitinib
INTRODUCTION: Acne is a common side effect of inflammatory bowel disease (IBD) treatment. We investigated the role of demodicosis in acne development in patients with IBD. METHODS: From 2019 to 2021, IBD patients with acneiform eruptions were referred for dermatological evaluation. We compared these patients according to the demodicosis status. RESULTS: Of 509 patients with IBD, 30 had acneiform eruptions. Among them, 20 had demodicosis. All were successfully treated without IBD treatment adjustments. Upadacitinib use was the only independent risk factor of demodicosis, occurring in 16 of 18 exposed patients. DISCUSSION: Demodicosis should be considered in patients with IBD having acneiform eruptions, particularly those receiving upadacitinib.
- 22 October 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (2) , 561-565
Open AccessDemodicosis Mimics Acneiform Eruptions in Patients With Inflammatory Bowel Disease Receiving Upadacitinib
INTRODUCTION: Acne is a common side effect of inflammatory bowel disease (IBD) treatment. We investigated the role of demodicosis in acne development in patients with IBD. METHODS: From 2019 to 2021, IBD patients with acneiform eruptions were referred for dermatological evaluation. We compared these patients according to the demodicosis status. RESULTS: Of 509 patients with IBD, 30 had acneiform eruptions. Among them, 20 had demodicosis. All were successfully treated without IBD treatment adjustments. Upadacitinib use was the only independent risk factor of demodicosis, occurring in 16 of 18 exposed patients. DISCUSSION: Demodicosis should be considered in patients with IBD having acneiform eruptions, particularly those receiving upadacitinib.
- Open Access
- 4 October 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 240-241
Response to comment on “Pregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis”
- 4 October 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 240-241
Open AccessResponse to comment on “Pregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis”
- Open Access
- 30 July 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (3) , 338-346
Knowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region
Background/Aims: Recently, histological mucosal assessment has gained momentum as a potential new treatment target for patients with inflammatory bowel disease (IBD) in the Asia-Pacific region. This study aimed to evaluate and compare the knowledge and acceptability of histological assessment among gastroenterologists across the region. Methods: A cross-sectional survey among gastroenterologists in the Asia-Pacific region was conducted and compared against a previous Australian survey. The questionnaire assessed knowledge and attitude towards the role and application of histology in IBD practice. Statistical analyses were employed to compare scores and identify predictors. Results: A total of 221 gastroenterologists from 12 countries, including 77 (34.8%) from Australia, responded to questionnaire, with 185 (83.7%) completing the survey. The mean knowledge score was 9.8 ± 3.3 (51.6%). There was no significant difference in the average score among countries (P= 0.53). IBD specialist (P< 0.01), doctoral degree (P= 0.02), and regular participation in IBD multidisciplinary meetings (P= 0.01) were associated with higher scores. Most respondents (90.7%) agreed on the importance of histology in IBD. While 54.6% of Australians perceived the role of histology as established, only 37.0% of Asians respondents considered this similarly (P= 0.02). Histological activity alone minimally influences treatment escalation in patients with endoscopic remission, but achieving combined histo-endoscopic remission often leads to therapy de-escalation. Conclusions: Although gastroenterologists in the Asia-Pacific region are aware of the role of histology in IBD, their knowledge remains limited, and its clinical utility is not widely adopted. There is a need to promote the routine use of standardized histological assessment in IBD practice.
- 30 July 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (3) , 338-346
Open AccessKnowledge and perspectives towards the use of histology in inflammatory bowel disease by gastroenterologists across the Asia-Pacific region
Background/Aims: Recently, histological mucosal assessment has gained momentum as a potential new treatment target for patients with inflammatory bowel disease (IBD) in the Asia-Pacific region. This study aimed to evaluate and compare the knowledge and acceptability of histological assessment among gastroenterologists across the region. Methods: A cross-sectional survey among gastroenterologists in the Asia-Pacific region was conducted and compared against a previous Australian survey. The questionnaire assessed knowledge and attitude towards the role and application of histology in IBD practice. Statistical analyses were employed to compare scores and identify predictors. Results: A total of 221 gastroenterologists from 12 countries, including 77 (34.8%) from Australia, responded to questionnaire, with 185 (83.7%) completing the survey. The mean knowledge score was 9.8 ± 3.3 (51.6%). There was no significant difference in the average score among countries (P= 0.53). IBD specialist (P< 0.01), doctoral degree (P= 0.02), and regular participation in IBD multidisciplinary meetings (P= 0.01) were associated with higher scores. Most respondents (90.7%) agreed on the importance of histology in IBD. While 54.6% of Australians perceived the role of histology as established, only 37.0% of Asians respondents considered this similarly (P= 0.02). Histological activity alone minimally influences treatment escalation in patients with endoscopic remission, but achieving combined histo-endoscopic remission often leads to therapy de-escalation. Conclusions: Although gastroenterologists in the Asia-Pacific region are aware of the role of histology in IBD, their knowledge remains limited, and its clinical utility is not widely adopted. There is a need to promote the routine use of standardized histological assessment in IBD practice.
- 23 June 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (1) , 176-184
Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease
Objectives: Our previous study revealed a correlation between fecal leukocyte esterase and fecal calprotectin levels. This study assessed the predictive value of fecal leukocyte esterase compared with fecal calprotectin and C-reactive protein of inflammatory bowel disease. Methods: Patients with inflammatory bowel disease who underwent ileocolonoscopy at National Taiwan University Hospital from March 2022 to March 2024 were included. Fecal leukocyte esterase and fecal calprotectin levels from stool samples collected within one month of endoscopy were analyzed. Active ulcerative colitis and Crohn’s disease were defined as Mayo endoscopic score ≥2 or simple endoscopic score for Crohn’s disease ≥7, respectively. Sensitivity, specificity, predictive values, and areas under the receiver operating characteristic curve were calculated using IBM SPSS Statistics 29. Results: Of the 203 patients (100 with ulcerative colitis and 103 with Crohn’s disease), fecal leukocyte esterase levels were significantly correlated with fecal calprotectin levels (r=0.425, p<0.001) and endoscopic severity in ulcerative colitis (r=0.432, p<0.001) and Crohn’s disease (r=0.311, p=0.001). For predicting Mayo endoscopic scores ≥2 in ulcerative colitis using fecal leukocyte esterase, fecal calprotectin, and C-reactive protein, areas under the curve were 0.731, 0.785, and 0.558, respectively. For predicting simple endoscopic scores for Crohn’s disease ≥7, areas under the curve were 0.706, 0.800, and 0.770, respectively. No significant difference was observed between fecal leukocyte esterase and fecal calprotectin. Conclusions: Fecal leukocyte esterase correlates with fecal calprotectin and predicts endoscopic severity in inflammatory bowel disease.
- 23 June 2025
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 64 (1) , 176-184
Fecal leukocyte esterase levels predict endoscopic severity as an alternative biomarker in inflammatory bowel disease
Objectives: Our previous study revealed a correlation between fecal leukocyte esterase and fecal calprotectin levels. This study assessed the predictive value of fecal leukocyte esterase compared with fecal calprotectin and C-reactive protein of inflammatory bowel disease. Methods: Patients with inflammatory bowel disease who underwent ileocolonoscopy at National Taiwan University Hospital from March 2022 to March 2024 were included. Fecal leukocyte esterase and fecal calprotectin levels from stool samples collected within one month of endoscopy were analyzed. Active ulcerative colitis and Crohn’s disease were defined as Mayo endoscopic score ≥2 or simple endoscopic score for Crohn’s disease ≥7, respectively. Sensitivity, specificity, predictive values, and areas under the receiver operating characteristic curve were calculated using IBM SPSS Statistics 29. Results: Of the 203 patients (100 with ulcerative colitis and 103 with Crohn’s disease), fecal leukocyte esterase levels were significantly correlated with fecal calprotectin levels (r=0.425, p<0.001) and endoscopic severity in ulcerative colitis (r=0.432, p<0.001) and Crohn’s disease (r=0.311, p=0.001). For predicting Mayo endoscopic scores ≥2 in ulcerative colitis using fecal leukocyte esterase, fecal calprotectin, and C-reactive protein, areas under the curve were 0.731, 0.785, and 0.558, respectively. For predicting simple endoscopic scores for Crohn’s disease ≥7, areas under the curve were 0.706, 0.800, and 0.770, respectively. No significant difference was observed between fecal leukocyte esterase and fecal calprotectin. Conclusions: Fecal leukocyte esterase correlates with fecal calprotectin and predicts endoscopic severity in inflammatory bowel disease.
- Open Access
- 6 March 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 200-206
Pregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis
- 6 March 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (2) , 200-206
Open AccessPregnancy and perinatal outcomes of mothers with inflammatory bowel disease in Taiwan: A national database analysis
- Open Access
- 5 December 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (2) , e00798
Clinical Characteristics, Management, and Outcomes of Colitis-Associated Colorectal Cancer and the Comparison With Sporadic Colorectal Cancer in Taiwan
INTRODUCTION: We explored the clinical characteristics, treatment, and outcomes of colitis-associated colorectal cancer (CAC) and compared with sporadic colorectal cancer in Taiwan. METHODS: In this retrospective study spanning 1987–2022, CACs diagnosed according to endoscopic and pathological reports from 14 tertiary centers were reported to our cohort. Clinical demographics, endoscopic findings, histological results, treatment modalities, and outcomes were analyzed. Sporadic colorectal cancer data were retrieved from the Cancer Registry Annual Report, Ministry of Health and Welfare, Taiwan. RESULTS: We enrolled 65 patients with CAC (median age: 56 years; male: 66.2%). Distal colon was the most common tumor location (41.5%). Of patients with ulcerative colitis, 77.2% had extensive colitis, and 76.5% had Mayo endoscopic subscores of ≥2. Moreover, 50% of lesions were nonpolypoid with indistinct borders in 66.7%. Signet-ring cell subtype consisted of 12.3%. Surveillance colonoscopy adherence was 78.4%, yet 51.3% interval cancers occurred. Disease stage 0–4 distribution was 15%, 20%, 13.3%, 20%, and 31.7%, respectively. Endoscopic resection was feasible for 14%, whereas 67.7% required surgery. During follow-up (median: 21.5 months), we recorded 23.2% recurrence and 34.5% mortality. Lesions with indistinct borders were associated with adverse outcomes (adjusted odds ratio = 11.5 [1.35–98.16]). Colitis-associated rectal cancers, diagnosed later (P < 0.001), had worse outcomes than sporadic rectal cancers. DISCUSSION: This is the largest Asian CAC cohort study, emphasizing the need for stringent disease control, improving detection, and reducing interval cancers. Signet-ring cell subtype was prevalent. Rectal colitis-associated cancers were diagnosed later with poorer outcomes than sporadic rectal cancers.
- 5 December 2024
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (2) , e00798
Open AccessClinical Characteristics, Management, and Outcomes of Colitis-Associated Colorectal Cancer and the Comparison With Sporadic Colorectal Cancer in Taiwan
INTRODUCTION: We explored the clinical characteristics, treatment, and outcomes of colitis-associated colorectal cancer (CAC) and compared with sporadic colorectal cancer in Taiwan. METHODS: In this retrospective study spanning 1987–2022, CACs diagnosed according to endoscopic and pathological reports from 14 tertiary centers were reported to our cohort. Clinical demographics, endoscopic findings, histological results, treatment modalities, and outcomes were analyzed. Sporadic colorectal cancer data were retrieved from the Cancer Registry Annual Report, Ministry of Health and Welfare, Taiwan. RESULTS: We enrolled 65 patients with CAC (median age: 56 years; male: 66.2%). Distal colon was the most common tumor location (41.5%). Of patients with ulcerative colitis, 77.2% had extensive colitis, and 76.5% had Mayo endoscopic subscores of ≥2. Moreover, 50% of lesions were nonpolypoid with indistinct borders in 66.7%. Signet-ring cell subtype consisted of 12.3%. Surveillance colonoscopy adherence was 78.4%, yet 51.3% interval cancers occurred. Disease stage 0–4 distribution was 15%, 20%, 13.3%, 20%, and 31.7%, respectively. Endoscopic resection was feasible for 14%, whereas 67.7% required surgery. During follow-up (median: 21.5 months), we recorded 23.2% recurrence and 34.5% mortality. Lesions with indistinct borders were associated with adverse outcomes (adjusted odds ratio = 11.5 [1.35–98.16]). Colitis-associated rectal cancers, diagnosed later (P < 0.001), had worse outcomes than sporadic rectal cancers. DISCUSSION: This is the largest Asian CAC cohort study, emphasizing the need for stringent disease control, improving detection, and reducing interval cancers. Signet-ring cell subtype was prevalent. Rectal colitis-associated cancers were diagnosed later with poorer outcomes than sporadic rectal cancers.